Research programme: angiogenesis inhibitors - MedexisAlternative Names: Angiomed Project; MED-A300; MED-A301
Latest Information Update: 10 Dec 2010
At a glance
- Originator Medexis
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Sep 2004 Compounds from this research programme are available for licensing (http://www.medexis-biotech.com)
- 06 Aug 2004 Preclinical trials in Cancer in Greece (unspecified route)